Digipath
CHM Cannabis
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/10/2018 6:00:00 PM - Followers: 81 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

Digipath
CHM Cannabis
GALT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update 11/13/2018 08:00:00 AM
GALT News: Current Report Filing (8-k) 11/13/2018 07:56:58 AM
GALT News: Quarterly Report (10-q) 11/13/2018 07:54:10 AM
GALT News: Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD A... 11/05/2018 08:00:00 AM
GALT News: Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference 10/15/2018 10:22:27 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#3490   This SA article disagrees. Conatus And Emricasan In buckysherm 12/10/18 06:00:00 PM
#3489   CNAT trial results were bad - they tanked Amatuer17 12/10/18 02:42:29 PM
#3488   Could this also be an indication that CNAT buckysherm 12/10/18 12:57:56 PM
#3487   Look at GLMD - the phase 3 trial Amatuer17 11/05/18 07:53:48 PM
#3486   I couldn't agree more. Keep your fingers crossed. mikeslife 11/05/18 05:13:09 PM
#3485   B.O. imo IF IF we get up two 1hb 11/05/18 01:51:51 PM
#3484   going UP on down biotech days. microcapbiotech 11/02/18 10:07:02 PM
#3483   I agree, caught my eye yesterday...note last two 1hb 11/01/18 03:06:40 PM
#3482   There's something happening here, microcapbiotech 11/01/18 11:31:27 AM
#3481   Pfizer Announces Clinical Development Agreement with Novartis to Amatuer17 10/29/18 06:54:17 AM
#3480   New Form 4: A Director bought 2000 thefamilyman 09/27/18 01:07:34 PM
#3479   New prospectus out: It covers the conversion of existing thefamilyman 09/25/18 01:04:59 PM
#3478   GRMD02 improves Keytruda effectiveness by 4 times ! buckysherm 09/22/18 07:31:06 PM
#3477   https://www.keytruda.com/head-and-neck-cancer/keytruda-clinical-trials/ buckysherm 09/22/18 07:29:14 PM
#3476   GALT UPGRADED! They got one from Seaport Chess Master 09/21/18 02:19:32 PM
#3475   Looks like Feuerstein taken to woodshed in article Chess Master 09/21/18 10:21:35 AM
#3474   Interesting article https://msmoneymoves.com/2018/09/20/market-not-grasping-the Amatuer17 09/20/18 10:11:45 PM
#3473   I hate to be "Debbie Downer" and I mikeslife 09/20/18 02:09:34 PM
#3472   Galt patients story : http://markanehornibrook.blogspot.com/?m=1 buckysherm 09/20/18 11:40:36 AM
#3471   Take A look 33% keytruba alone, 50% with Coolec78 09/20/18 11:39:56 AM
#3470   That’s right ! 17% better on hard buckysherm 09/20/18 11:34:50 AM
#3469   But still it is 17%more than keytruba alone Coolec78 09/20/18 10:38:54 AM
#3468   The overall impact % is 50 which is Amatuer17 09/20/18 10:31:23 AM
#3467   After that good news this morning, we might buckysherm 09/20/18 10:11:21 AM
#3466   Ketruda is PD-1 and Yervoy is CTLA and Amatuer17 09/19/18 11:54:29 PM
#3465   Thanks Amateur. I found it in the thefamilyman 09/19/18 08:35:38 PM
#3464   The Yervoy trial was stopped as they moved Amatuer17 09/19/18 06:46:16 PM
#3463   Michael Golden has this comment at the end thefamilyman 09/19/18 10:51:39 AM
#3462   FYI: mikeslife 09/19/18 09:38:43 AM
#3461   He writes in depth but acts like pumper. His Amatuer17 09/18/18 07:22:40 AM
#3460   Anyone see this blog posting - very in Chess Master 09/17/18 12:52:50 PM
#3459   It is a complement buckysherm 09/13/18 12:59:53 PM
#3458   Not sure if this is complement or sarcasm. I Amatuer17 09/13/18 10:20:55 AM
#3457   I Amatuer17 09/13/18 10:20:45 AM
#3456   Not sure if this is complement or sarcasm. I Amatuer17 09/13/18 10:20:20 AM
#3455   Not sure if this is complement or sarcasm. I Amatuer17 09/13/18 10:19:31 AM
#3454   Thank you amatuer, for discouraging me out of buckysherm 09/13/18 10:08:35 AM
#3453   http://cancerres.aacrjournals.org/content/72/22/5757 buckysherm 09/12/18 07:27:05 AM
#3452   https://www.businesswire.com/news/home/20180208005344/en/Modified-Citrus-Pectin- buckysherm 09/11/18 01:26:51 PM
#3451   https://fintel.io/b/galt-galectin-therapeutics-analysis-and-research-report-1777 mikeslife 09/11/18 11:01:22 AM
#3450   https://emerginggrowth.com/galectin-therapeutics-nasdaq-galt-drops-phase-3-cance mikeslife 09/09/18 12:11:38 PM
#3449   Here is the link to webcast and slides http://wsw.com/webcast/rrshq28/galt/ Th Amatuer17 09/08/18 10:10:35 AM
#3448   Galectin Therapeutics Inc (GALT:NASDAQ) Rocketstockpix 09/07/18 03:01:13 PM
#3447   sure is. emerginggrowth.com has a lot to do Rocketstockpix 09/07/18 02:55:26 PM
#3446   Excellent article by Emerginggrowth.com Rocketstockpix 09/07/18 02:50:55 PM
#3445   FYI: mikeslife 09/07/18 10:51:51 AM
#3444   He is trying to read tealeaves based on Amatuer17 09/06/18 07:51:49 AM
#3443   Very interesting: mikeslife 09/05/18 04:18:22 PM
#3442   This article supports the contention that GR-MD-02 could thefamilyman 09/02/18 11:03:30 AM
#3441   https://www.nature.com/articles/s41374-018-0119-3 buckysherm 09/01/18 07:19:16 PM
PostSubject